Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes.

Junko OyaTomoko NakagamiYukiko HasegawaYuichiro KondoAki KatamineMika ShimizuRyo KubotaRika SudaTetsuya Babazono

Published in: Diabetology international (2024)

Once-daily IDegLira had greater effects on HbA1c and a lesser increase in insulin doses than IDegAsp when patients are switched from basal insulin therapy. Moreover, the effect on HbA1c was enhanced in patients with high HbA1c levels at baseline.

Keyphrases

type diabetes
glycemic control
end stage renal disease
newly diagnosed
chronic kidney disease
physical activity
stem cells
prognostic factors
peritoneal dialysis
metabolic syndrome
patient reported outcomes
skeletal muscle
weight loss
cell therapy